ArticleFrontiers in pharmacology2026
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations: a cost-utility analysis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fuzuloparib, a novel PARP inhibitor, has demonstrated efficacy in patients with HER2-negative metastatic breast cancer (MBC) harboring germline BRCA1/2 mutations. The addition of apatinib, an anti-angiogenic agent, enhances treatment outcomes. However, the economic value of these strategies remains unclear. Objective: To evaluate the cost-utility of fuzuloparib with or without apatinib compared with standard chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA mutations from the Chinese healthcare system perspective. Methods: A partitioned survival model was developed over a 10-year time horizon. Clinical inputs were derived from the phase III FABULOUS trial. Survival data were reconstructed and extrapolated using parametric models. Costs and utilities were obtained from published literature and Yaozh databases. Outcomes were measured in quality-adjusted life years (QALYs) and incremental cost-utility ratios (ICURs). A willingness-to-pay (WTP) threshold of ¥199,330/QALY was applied. Deterministic and probabilistic sensitivity analyses were conducted to assess model uncertainty. Results: In the base-case analysis, total costs were ¥266,989.27 for fuzuloparib plus apatinib (FA), ¥230,151.42 for fuzuloparib monotherapy (FM), and ¥188,774.18 for standard chemotherapy (SC). Corresponding QALYs were 1.5669, 1.4128, and 1.1477, respectively. Compared with SC, the ICURs were ¥186,581.80 per QALY for FA and ¥156,081.63 per QALY for FM, both lower than the WTP threshold. Compared with FM, the ICUR was ¥239,051.59 per QALY for FA. Sensitivity analyses confirmed that the probability of the FA, FM and SC being cost-effective were 29.15%, 42.72%, and 28.13% at the WTP threshold. Conclusion: From the perspective of the Chinese healthcare system, both fuzuloparib plus apatinib and fuzuloparib monotherapy is cost-effective compared with standard chemotherapy at current WTP threshold. However, FA was not cost-effective relative to FM at the current Chinese WTP threshold.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.